GSWM
ICPT

Golden State Wealth Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Golden State Wealth Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$1K – 375
2021
Q3 		$1K Buy
+100
New +$1.6K ﹤0.01% 307
2019
Q2 		– Sell
-206
Closed -$23K – 1175
2019
Q1 		$23K Buy
+206
New +$22.5K 0.01% 599

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Golden State Wealth Management's ICPT Position: Q4 2021 in Review

Golden State Wealth Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 100 shares — an estimated $1K sold.

Golden State Wealth Management first reported a position in ICPT in Q1 2019 and held it in 2 quarters. The position peaked at $23K in Q1 2019. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.

  • Golden State Wealth Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Golden State Wealth Management sold 100 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1K.
  • Golden State Wealth Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Golden State Wealth Management's Intercept Pharmaceuticals, Inc. position peaked at $23K in Q1 2019.
  • 147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.

Based on Golden State Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.